Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 8/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796230 | 0.91 | LTB4R (0.38) | LTB4RCNR2CNR1TSHRGABRA1 | |
| SCHEMBL19796239 | 0.91 | RARB (0.37) | LTB4RCNR2CNR1LTB4R2RARB | |
| SCHEMBL19796402 | 0.90 | CNR2 (0.38) | LTB4RCNR2CNR1TSHRRARB | |
| SCHEMBL19796608 | 0.89 | CNR2 (0.38) | CNR2CNR1TSHRRARARARB | |
| SCHEMBL19804228 | 0.88 | L3MBTL1 (0.35) | LTB4RCNR2CNR1LTB4R2TSHR | |
| SCHEMBL19796238 | 0.88 | ALOX5 (0.36) | LTB4RTSHRGABRA1GABRB2ALOX5 | |
| SCHEMBL19796279 | 0.87 | LTB4R (0.40) | LTB4RCNR2CNR1TSHRPOLB | |
| SCHEMBL19804494 | 0.86 | RARB (0.41) | LTB4RLTB4R2RARARARBRARG | |
| SCHEMBL19796345 | 0.86 | LTB4R (0.36) | LTB4RTSHRPOLBAPEX1HTT | |
| SCHEMBL19796226 | 0.85 | LTB4R (0.39) | LTB4RCNR2CNR1TSHRGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | LTB4R 2415/4885CNR2 1075/4885CNR1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.